These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 18444882

  • 1. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.
    Ganguly S, Das NK, Panja M, Pal S, Modak D, Rahaman M, Mallik S, Guha SK, Pramanik N, Goswami R, Barbhuiya JN, Saha B, Chatterjee M.
    J Infect Dis; 2008 Jun 15; 197(12):1762-71. PubMed ID: 18444882
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.
    Mukhopadhyay D, Das NK, De Sarkar S, Manna A, Ganguly DN, Barbhuiya JN, Maitra AK, Hazra A, Chatterjee M.
    Trans R Soc Trop Med Hyg; 2012 Nov 15; 106(11):668-76. PubMed ID: 22920931
    [Abstract] [Full Text] [Related]

  • 3. Post-kala-azar dermal leishmaniasis--an overview.
    Ganguly S, Das NK, Barbhuiya JN, Chatterjee M.
    Int J Dermatol; 2010 Aug 15; 49(8):921-31. PubMed ID: 21128917
    [Abstract] [Full Text] [Related]

  • 4. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
    Ansari NA, Ramesh V, Salotra P.
    J Infect Dis; 2006 Oct 01; 194(7):958-65. PubMed ID: 16960784
    [Abstract] [Full Text] [Related]

  • 5. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.
    Ganguly S, Mukhopadhyay D, Das NK, Chaduvula M, Sadhu S, Chatterjee U, Rahman M, Goswami RP, Guha SK, Modak D, Mallik S, Gonju D, Pramanik N, Barbhuiya JN, Saha B, Chatterjee M.
    J Invest Dermatol; 2010 Apr 01; 130(4):1013-22. PubMed ID: 20032994
    [Abstract] [Full Text] [Related]

  • 6. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
    Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, Kharazmi A, Theander TG.
    J Pathol; 1999 Dec 01; 189(4):615-22. PubMed ID: 10629566
    [Abstract] [Full Text] [Related]

  • 7. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N.
    J Immunol; 2007 Oct 15; 179(8):5592-603. PubMed ID: 17911647
    [Abstract] [Full Text] [Related]

  • 8. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
    Saha S, Mazumdar T, Anam K, Ravindran R, Bairagi B, Saha B, Goswami R, Pramanik N, Guha SK, Kar S, Banerjee D, Ali N.
    J Clin Microbiol; 2005 Mar 15; 43(3):1269-77. PubMed ID: 15750095
    [Abstract] [Full Text] [Related]

  • 9. Lesional T-cell subset in post-kala-azar dermal leishmaniasis.
    Rathi SK, Pandhi RK, Chopra P, Khanna N.
    Int J Dermatol; 2005 Jan 15; 44(1):12-3. PubMed ID: 15663651
    [Abstract] [Full Text] [Related]

  • 10. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar.
    Ansari NA, Saluja S, Salotra P.
    Clin Immunol; 2006 Jun 15; 119(3):339-45. PubMed ID: 16540374
    [Abstract] [Full Text] [Related]

  • 11. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
    Rahman KM, Islam S, Rahman MW, Kenah E, Ghalib CM, Zahid MM, Maguire J, Rahman M, Haque R, Luby SP, Bern C.
    Clin Infect Dis; 2010 Jan 01; 50(1):73-6. PubMed ID: 19951168
    [Abstract] [Full Text] [Related]

  • 12. Decreased presence of Langerhans cells is a critical determinant for Indian Post kala-azar dermal leishmaniasis.
    Mukherjee S, Mukhopadhyay D, Braun C, Barbhuiya JN, Das NK, Chatterjee U, von Stebut E, Chatterjee M.
    Exp Dermatol; 2015 Mar 01; 24(3):232-4. PubMed ID: 25580856
    [Abstract] [Full Text] [Related]

  • 13. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.
    Trop Med Int Health; 2012 Nov 01; 17(11):1345-8. PubMed ID: 22882665
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.
    Kaushal H, Bras-Gonçalves R, Avishek K, Kumar Deep D, Petitdidier E, Lemesre JL, Papierok G, Kumar S, Ramesh V, Salotra P.
    Clin Exp Immunol; 2016 Jul 01; 185(1):50-60. PubMed ID: 26948150
    [Abstract] [Full Text] [Related]

  • 15. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
    Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M.
    J Infect Dis; 2011 Nov 01; 204(9):1427-36. PubMed ID: 21933878
    [Abstract] [Full Text] [Related]

  • 16. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases.
    Sharma MC, Gupta AK, Verma N, Das VN, Saran R, Kar SK.
    J Commun Dis; 2000 Mar 01; 32(1):67-8. PubMed ID: 11129569
    [No Abstract] [Full Text] [Related]

  • 17. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
    Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gilleman Q, Thunissen C, Hinckel BCB, Pearson C, Gardner BL, Airs S, de la Roche M, Hayes K, Hafezi H, Falconar AK, Eisa O, Saad A, Khanal B, Bhattarai NR, Rijal S, Boelaert M, El-Safi S, Sundar S, Miles MA.
    Front Cell Infect Microbiol; 2018 Mar 01; 8():427. PubMed ID: 30619774
    [Abstract] [Full Text] [Related]

  • 18. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.
    Das ML, Deb M, Karki BM, Sarif M, Khanal B, Bhattacharya SK, Agrawal S, Koirala S.
    Southeast Asian J Trop Med Public Health; 2007 Jul 01; 38(4):619-25. PubMed ID: 17882997
    [Abstract] [Full Text] [Related]

  • 19. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar 01; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 20. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D, Mukherjee S, Ghosh S, Roy S, Saha B, Das NK, Chatterjee M.
    Int J Dermatol; 2016 May 01; 55(5):e250-5. PubMed ID: 26536363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.